Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSFWT7)

Drug Name
Famitinib Drug Info
Synonyms
Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
PubChem CID
16662431
CAS Number
CAS 945380-27-8
TTD Drug ID
DMSFWT7
INTEDE Drug ID
DR1843

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Vascular endothelial growth factor receptor 3 (FLT-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [7]
PI-88 DMGZPX6 Hepatocellular carcinoma 2C12.02 Phase 3 [8]
Taberminogene vadenovec DMW5PHL Vascular restinosis BE2Z Phase 3 [9]
ABT-869 DMREDYP Solid tumour/cancer 2A00-2F9Z Phase 3 [10]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [11]
VATALANIB DMY0UEQ Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [14]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [15]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [16]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [17]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [18]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [21]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [23]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [24]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [25]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [26]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [26]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [27]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [28]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [15]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [24]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [14]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [29]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [13]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [30]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [22]
PMID25656651-Compound-21a DMCKAON N. A. N. A. Patented [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 1 (FLT-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [7]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [33]
OCV-101 DMT9QI2 Pancreatic cancer 2C10 Phase 2 [34]
LY3012212 DMRVEHY Arteriosclerosis BD40 Phase 2 [35]
OTSGC-A24 DMN0ZQ5 Colorectal cancer 2B91.Z Phase 1/2 [36]
CEP-11981 DMYDTJ6 Solid tumour/cancer 2A00-2F9Z Phase 1 [37]
EW-A-401 DM3VC6T Peripheral vascular disease BD4Z Phase 1 [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [39]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [26]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [40]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [23]
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [41]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [28]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [39]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [42]
Lestaurtinib DMQ2AIJ Acute myeloid leukaemia 2A60 Approved (orphan drug) [43]
BMS-690514 DMX302C Chronic pain MG30 Phase 2 [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [24]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [45]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [26]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [46]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [47]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [23]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [27]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [48]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [49]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [50]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [51]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [53]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [55]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [56]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [50]
Verapamil DMA7PEW Angina pectoris BA40 Approved [57]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [58]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [59]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [60]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [61]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [62]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [63]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [55]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [64]
Verapamil DMA7PEW Angina pectoris BA40 Approved [65]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [67]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [68]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [69]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [70]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [64]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [71]
Estrone DM5T6US Acne vulgaris ED80 Approved [72]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [73]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [74]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [75]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [76]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [77]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [78]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [79]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [80]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [81]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [82]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [83]
Verapamil DMA7PEW Angina pectoris BA40 Approved [84]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [79]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [2]
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [2]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [2]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [2]
Vascular endothelial growth factor receptor 1 (FLT-1) TT2Q6G1 VGFR1_HUMAN Inhibitor [2]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [2]
Vascular endothelial growth factor receptor 3 (FLT-4) TTDCBX5 VGFR3_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [3]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [3]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7886).
2 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
3 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
4 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
6 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
7 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
8 Company report (Medigen)
9 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
10 Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
12 Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
13 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
14 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
16 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
19 National Cancer Institute Drug Dictionary (drug id 452042).
20 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
21 Clinical pipeline report, company report or official report of MedImmune (2011).
22 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
23 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
24 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
25 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
27 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
28 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
30 Company report (Neuronova)
31 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
32 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
33 National Cancer Institute Drug Dictionary (drug id 695817).
34 Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
35 Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
36 J Clin Oncol 33, 2015 (suppl 3; abstr 65).
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
38 DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
40 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
41 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
42 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
43 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
44 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
45 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
46 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
47 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
48 Clinical pipeline report, company report or official report of Exelixis (2011).
49 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
50 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
51 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
52 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
53 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
54 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
55 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
56 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
57 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
58 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
59 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
60 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
61 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
62 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
63 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
64 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
65 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
66 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
67 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
68 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
69 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
70 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
71 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
72 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
73 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
74 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
75 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
76 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
77 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
78 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
79 Drug Interactions Flockhart Table
80 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
81 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
82 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
83 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
84 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.